Vancomycin is a commonly used antibiotic due to the high burden of methicillin-resistant Staphylococcus aureus infections. This study aimed to describe the pharmacokinetics (PK) of vancomycin in Australian Indigenous patients with severe sepsis, and advise an optimal dosing strategy. A population PK study was conducted in a remote Australian intensive care unit (ICU). Serial plasma samples were collected over one to two dosing intervals and assayed by validated chromatography. Concentration-time data collected were analysed using Pmetrics® software. The final population PK model was then used for Monte Carlo dosing simulations to determine optimal loading and intermittent maintenance doses. Fifteen Indigenous subjects were included for analysis with a median (interquartile range, IQR) age, weight and creatinine clearance (CrCL) of 43 (34-46) years, 73 (66-104) kg and 99 (56-139) ml/minute respectively. A two-compartment model described the data adequately. Vancomycin clearance (CL) and volume of distribution of the central compartment (Vc) were described by CrCL and patient weight respectively. Median (IQR) CL, Vc, distribution rate constants from central to peripheral, and from peripheral to central compartments were 4.6 (3.8-5.6) litres per hour, 25.4 (16.1-31.3) litres, 0.46 (0.28-0.52)/hour and 0.25 (0.12-0.37)/hour respectively. No significant interethnic PK differences were observed in comparison to published data. Therapeutic loading doses were significantly dependent on both weight and CrCL, whereas maintenance doses were dependent on CrCL. In the absence of severe renal impairment, initiation of maintenance dose eight hours post-loading dose achieved higher probability of target attainment at 24 hours. This is the first report of vancomycin PK in this patient group.
1
. Empirical vancomycin therapy is commonly used in Indigenous patients presenting with sepsis in rural and remote health centres. This is due to the high prevalence of community-acquired methicillinresistant Staphylococcus aureus (MRSA) colonisation and infections in patients from remote communities, especially in Central Australia 2, 3 . Therapeutic drug monitoring (TDM) is almost always utilised for vancomycin therapy in the intensive care unit (ICU) due to its narrow therapeutic window 4 . Vancomycin exhibits a mixed concentration-dependent and time-dependent bacterial kill characteristic, that appears best represented by the ratio of 24-hour area under the drug concentration-time curve to the bacterial minimum inhibitory concentration (AUC 0-24 : MIC) 5 , and the commonly accepted pharmacokinetic/ pharmacodynamic (PK/PD) target is an AUC 0-24 :MIC ratio of ≥400. Vancomycin is subject to significant PK changes in critical illness such as increases in volume of distribution and increases or decreases in vancomycin clearance (CL) due to augmented renal clearance or acute kidney injury, respectively. These scenarios can dramatically complicate vancomycin dosing 6, 7 . A recent systematic review identified interethnic differences in PK for numerous antibiotics 8 . Various physiological characteristics reported in the Australian Indigenous people raise the question of whether PK differences exist when compared with non-Indigenous populations. Relative to non-Indigenous comparators, young Indigenous adults are reported to have 30% fewer nephrons 9 , smaller body mass, slimmer extremities and higher central fat 10 which together may be associated with altered CL and volumes of distribution of renally cleared drugs. As current guidelines are predominantly extracted from studies performed in Caucasian and Asian populations, the PK of antibiotics need to be described to ensure current dosing regimens are optimal for other patient populations.
This study aimed to describe the population PK of vancomycin in Indigenous Australians with severe sepsis and develop optimised dosing regimens that maximise the probability of PK/PD target attainment.
Patients and methods
A prospective, observational, population PK study was conducted in the ICU of an Australian remote teaching hospital.
Ethics
Ethical clearance was approved by the local (Central Australian Human Research Ethics Committee, approval HREC-13-149) and university (The University of Queensland Human Research Ethics Committee, approval 2013000904) Ethics Committees. Written consent was obtained from all participants/next of kin.
Study population
The inclusion criteria were: 1) Australian Indigenous, 2) ≥18 years of age, 3) confirmed or suspected severe sepsis 11 within the previous 48 hours, 4) prescribed with vancomycin, and 5) an arterial line in situ. The exclusion criteria were: 1) creatinine clearance (CrCL) <10 ml/minute, 2) requiring haemodialysis or continuous renal replacement therapy, and 3) pregnancy. The target sample size was 12 to 24 subjects, which is considered sufficient to describe the most important descriptors of altered PK and for defining appropriate antibiotic doses 12 .
Study protocol
The vancomycin (DBL Vancomycin®; Hospira Australia, Melbourne, Victoria) was administered via a central venous catheter and the dose and dosing interval were determined by the treating physician. Blood samples were collected in lithium heparin tubes from the patient's arterial line over one dosing interval at the following timepoints: 0, 90, 180, 210, 240, 300, 360, 420, 480 and 720 minutes from initiation of infusion. A second set of samples was obtained the next day if feasible. Demographics, clinical information, and routine laboratory test results performed on the study days were also recorded.
Sample handling and storage
Blood samples were placed in a drug refrigerator at 2°C to 8°C after sampling. They were then centrifuged at 5,000 revolutions per minute for six minutes within eight hours of collection. The plasma supernatant was pipetted into 1 ml cryovials and stored in a freezer at -70°C. At the end of subject recruitment, samples were packed with dry ice and freighted to the Burns, Trauma & Critical Care Research Centre, The University of Queensland, for drug assay.
Drug assay
Vancomycin was measured in plasma (0.2 to 100 mg/l) by a validated high-pressure liquid chromatography-mass spectroscopy/mass spectroscopy method on a Shimadzu Nexera2 ultra-high pressure liquid chromatography system coupled to a Shimadzu 8030+ triple quadrupole mass spectrometer (Shimadzu, Kyoto, Japan). For routine analysis, separations were performed using validated hydrophilic interaction liquid chromatography (HILIC), however a reverse phase chromatography was also validated to enable orthogonal analysis in cases of suspected chromatographic interference.
Sample (100 µl) was spiked first with internal standard (teicoplanin) and then treated with acetonitrile to precipitate proteins. Dichloromethane was then used to remove lipid soluble components from the aqueous supernatant. An aliquot of 0.5 µl of the aqueous supernatant was injected onto the high-pressure liquid chromatography-mass spectroscopy/mass spectroscopy.
Two separate, orthogonal chromatographies (HILIC or reversed phase columns with different gradients of the same mobile phase components) were validated for the measurement of vancomycin. Mobile Phase A was 0.1% formic acid in water (v/v), and Mobile Phase B was 100% acetonitrile with 0.1% formic acid (v/v). The default (HILIC) chromatography used a SeQuant zic-HILIC 2.1 x 20 mm (5.0 μm) analytical guard column and a gradient going from 80% B to 0% B and back again for a 5.5 minute run-time. The alternative (reverse phase) chromatography used a Restek Pinnacle DB IBD column, 2.1 x 50 mm (1.9 μm) and the gradient went from 5% B to 95% B and back again for a 6.5 minute run-time.
Vancomycin was monitored by positive mode electrospray at MRMs (multiple reaction monitoring) of 746.1→144.2 and 725.6→144.1. Teicoplanin was monitored in positive mode at 940.8→316.1.
The assay method was validated for linearity, lower limits of quantitation, matrix effects, recovery, reinjection stability and precision and accuracy using the Food and Drug Administration criteria for bioanalysis 13 . The precision and accuracy were within 2.2% and 9.1% for the default HILIC chromatography.
Population PK modelling
Concentration-time data from the plasma samples were described by compartment models using the Pmetrics® software package (version 1.4.2) for R® (version 3.2.2). Various demographic and clinical data collected (e.g. weight, measured CrCL, sickness severity scores) were tested for inclusion into the model as covariates. The covariate was included into the model if it improved the log likelihood (P <0.05) and/or the goodness-of-fit plots.
Model diagnostics
Model evaluation was performed by visual assessment of goodness-of-fit of the population and individual predicted concentration versus observed concentration plots. The predictive performance was assessed on mean prediction error (bias) and the mean biased adjusted squared prediction error (imprecision) of the population and individual posterior predictions. Finally, visual predictive check plots were generated from the final model. Appropriate distribution of the observed data within the simulated data was visually assessed.
Monte Carlo dosing simulation
Monte Carlo simulation was performed to determine optimal loading doses for various doses (15, 20, 25, 30, 35 and 40 mg/kg), weights (60, 80 and 100 kg) and CrCL (20, 50, 100, 130 and 170 ml/minute). The infusion rate used for all doses during simulation was 1,000 mg/hour. The simulations measured the probability of maintaining vancomycin concentration between 15 and 25 mg/l for a minimum of 80% of the dose interval from time 0 to 720 minutes.
The doses which achieved the highest probability of target attainment (PTA) were subsequently incorporated into specified maintenance dosing regimens (500 mg 8, 12 and 24-hourly; 1,000 mg 6, 8, 12 and 24-hourly; 2,000 mg 8, 12 and 24-hourly) for further simulations. PTA of the maintenance regimens assessed the likelihood of maintaining the vancomycin concentration between 15 and 25 mg/l for at least 80% of 24 hours, 24 hours post-end of loading dose interval.
Dosing simulations were repeated for the likelihood of attaining AUC:MIC ≥400 against different MICs (0.125 to 4 mg/l) for 24 hours, 24 hours post-end of loading dose interval (36 to 60 hours post-commencement of dosing for a CrCL of 20 ml/minute; 32 to 56 hours post-commencement of dosing for CrCL ≥50 ml/minute). The dosing regimens with the highest PTA were compared with the two different simulations for maintenance doses.
Statistical analysis
Continuous data were presented as median (interquartile range, IQR) and categorical data as counts (%).
Results
Fifteen Australian Indigenous patients were available for analysis inclusive of 216 blood samples. The demographics and clinical information are presented in Table 1 .
Population PK model building
A two-compartment model described the data adequately. CrCL and total body weight (TBW) were the only covariates which improved the population PK model significantly. The final model is described as:
Where TVCL is the typical value of CL, CL is the population parameter estimate of CL, TVV c is the typical value of V c , V c is the population parameter estimate of volume of the central compartment and TBW is total body weight. The goodness-of-fit for the individual and population predicted concentrations versus observed concentrations plots and visual predictive check plots were considered acceptable ( Figure 1 ). The population PK parameter estimates described by the final model are presented in Table 2 . 
Monte Carlo dosing simulations
The dosing simulations revealed the loading doses with highest PTA are dependent on both CrCL and TBW, whereas the maintenance dose associates significantly with CrCL. The PTA of maintenance dosing regimens for a trough concentration of 15-25 mg/l 24 hours post-loading dose against various CrCL is presented in Table 3 . Regimens with the highest PTA were then selected for the dosing table presented in Table 4 and dosing graph in Figure 2 .
The dosing simulations demonstrate that patients with lower TBW achieved slightly lower vancomycin concentrations when compared with higher TBW. Furthermore, the highest PTA of trough concentrations 15-25 mg/l 24 hours postloading dose are mostly between 50% and 70%.
When comparing the PTA from the two dosing simulation targets (trough concentrations and AUC:MIC), we found a high correlation of dosing regimens with highest PTA between the two sets of simulations for an MIC of 1 mg/l. Regimens with the same total daily dose but different dosing intervals manifested similar PTA, and regimens with less frequent dosing generally demonstrated a slightly lower PTA (e.g. 1.5 g twice daily achieved lower PTA than 1 g three times daily).
Discussion

Summary of principal findings
A large inter-individual variability was observed in the vancomycin PK which was significantly associated with differences in patients' TBW and CrCL. We found that optimal loading doses are heavily dependent on both TBW and CrCL, whereas maintenance doses are dependent on CrCL. We have presented a dosing table that can be used to maximise achievement of therapeutic concentrations for the first 24 hours post-loading dose. However, due to high vancomycin inter-individual PK variability, dosing regimens must be adjusted in accordance with conventional TDM strategies 24 hours post-loading dose.
Findings of the present study in light of previously published research
The estimated median CL (4.6 litres per hour) in the Indigenous patients was similar to other published data in critically patients with comparable CrCL (3.5 to 5.9 litres per hour), and like previous studies, CrCL remained the most important determinant of vancomycin PK [14] [15] [16] . This supports the finding highlighted in a recent systematic review, that interethnic differences in PK are unlikely for the CL of an antibiotic where glomerular filtration is the predominant mechanism of elimination 8 . Furthermore, we observed a large inter-individual variability for V c in our patient group. The median V c is 0.35 l/kg, which is similar to critically ill patients in other populations (0.19 to 0.41 l/kg) 14, 15 . These results do not support the presence of interethnic PK differences for vancomycin, or that at the very least, they suggest that any population-level difference is not clinically significant.
Loading doses are now considered important for rapidly achieving effective vancomycin exposures in critically ill patients. This practice is supported by data demonstrating that low vancomycin exposure (AUC:MIC ratio <430 for Etest and <398.5 for broth microdilution methods of MIC determination) for the first 24 to 48 hours of therapy is an independent factor for higher mortality and treatment failure in MRSA bacteraemia 17, 18 . In our dosing simulations, we found that the magnitude of loading dose required is affected by TBW and CrCL. The importance of CrCL is a novel observation, in some ways, with patients with a higher CrCL requiring the first maintenance dose to be administered earlier than in patients with lower CrCL. We proposed a first maintenance dose at eight hours in these scenarios. The major output from our dosing simulations was the development of a dosing algorithm which incorporates CrCL, creatinine clearance. ∫ Dosing regimens must be adjusted in accordance with conventional therapeutic drug monitoring strategies 24 hours postloading dose. loading doses and maintenance dosing regimens with the highest PTA.
Strengths and limitations
The Indigenous Australians are a unique ethnic group with very distinctive physiology. This study was able to recruit 15 Indigenous patients with severe sepsis, which is highly prevalent in Australian remote communities. There is currently very limited PK data available to guide optimal antibiotic dosing.
On the other hand, an association of PK/PD target attainment with an altered clinical outcome could not be assessed due to the small sample size. Furthermore, samples were not collected from the site of infection (e.g. epithelial lining fluid in pneumonia) and thus, our dosing recommendations relate to the achievement of target exposures in blood only. Finally, a larger sample size may have enabled other covariates to be included in the final model, although it is unlikely they would significantly alter the dosing algorithm.
Understanding the possible mechanism
The impact of drug CL on loading doses for vancomycin therapy is usually neglected. However, the process of vancomycin elimination would have initiated shortly after it reached a detected concentration in the plasma. For a drug that is predominantly eliminated via the renal route and with a mixed concentration-and time-dependent PD property, CrCL naturally becomes a significant determinant of early achievement of therapeutic target.
Meaning of this study and implications for practice
It is generally accepted that a TDM target for vancomycin intermittent infusions is a trough concentration between 15 and 20 mg/l. However, this target has also been shown to poorly correlate with an AUC of 400 mg.hour/litre due to high inter-individual variability 19 . In our simulations, however, we have found a high correlation between PTA of AUC of 400 mg.hour/litre and trough concentration between 15 and 25 mg/l. To some extent, this result supports the ongoing use of trough concentration measurements for TDM where it is not possible to more accurately characterise AUC:MIC in individual patients.
We would also point out that the commonly used empirical regimen of 1 g 12-hourly only achieved acceptable PTAs for patients with a CrCL of 50 ml/minute in our dosing simulations. Furthermore, the PTA of 50% to 70% for most recommended regimens denotes the requirement of dose adjustments for 30% to 50% of patients. Due to changes in renal function and PK alterations in critical illness, continuous TDM throughout the course of vancomycin therapy is still recommended.
Our dosing simulations have demonstrated drastically low PTA of AUC:MIC for MICs ≥1.5 mg/l for most maintenance dosing regimens, which is consistent with the association of a MIC ≥1.5 mg/l and higher mortality 18 . This observation emphasises the challenges in the treatment of MRSA infections with high MICs. Whilst the risk of toxicity also needs to be considered, unusually high doses may be required to attain the PK/PD target for increasing clinical cure and potentially survival in the presence of less susceptible pathogens.
Implications for future research
The dosing algorithm proposed in this study was aimed to achieve early PK/PD target attainment in the setting of critical illness. A study is needed to compare the PTA of this algorithm with conventional dosing guidelines. Furthermore, multicentre clinical trials may also be needed to assess the clinical outcomes in patients with confirmed MRSA infection, comparing those who have achieved early PK/PD target attainment to those who have not.
